Tucatinib

What is Tucatinib?[edit | edit source]

Tucatinib (Tukysa) is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

This medicine is used with the medicines trastuzumab and capecitabine to treat adults with:

human epidermal growth factor receptor-2 (HER2) positive breast cancer that has spread to other parts of the body such as the brain (metastatic), or that cannot be removed by surgery, and
who have received one or more anti-HER2 breast cancer treatments.

Tucatinib An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity.
Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.

Avoid concomitant use with :

Recommended Dosage

The recommended dosage of Tukysa is 300 mg taken orally twice daily in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity.
For patients with severe hepatic impairment, the recommended dosage is 200 mg orally twice daily.

Administration

Take Tukysa exactly as your healthcare provider tells you.
Tukysa is used with the medicines trastuzumab and capecitabine. Your healthcare provider will tell you the dose of trastuzumab and capecitabine you will take and how you will receive them.
Take Tukysa 2 times a day, with or without a meal.
Take Tukysa about 12 hours apart or at the same times every day.
Swallow Tukysa tablets whole. Do not chew, crush, or split Tukysa tablets before swallowing. Do not take Tukysa tablets if they are broken, cracked, or damaged.
If you vomit or miss a dose of Tukysa, take your next dose at your regular time.

This medicine is available in fallowing doasage form:

This medicine is available in fallowing brand namesː

Common possible side effects and laboratory abnormalities of this medicine include:

diarrhea
rash, redness, pain, swelling or blisters on the palms of your hands or soles of your feet
nausea
tiredness
increased liver function blood tests
vomiting
mouth sores (stomatitis)
decreased appetite
stomach-area (abdomen) pain
headache
low red blood cell counts (anemia)
rash

Tukysa may cause serious side effects, including:

Severe diarrhea, including dehydration, acute kidney injury, and death, has been reported. Administer antidiarrheal treatment as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue Tukysa based on severity.
Severe hepatotoxicity has been reported on Tukysa. Monitor ALT, AST and bilirubin prior to starting Tukysa, every 3 weeks during treatment and as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue Tukysa based on severity.
Tukysa can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Tukysa can cause fetal harm when administered to a pregnant woman.
There are no available human data on Tukysa use in pregnant women to inform a drug-associated risk.

The safety and effectiveness of Tukysa in pediatric patients have not been established.

Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) .
Dispense to patient in original container only. Store in original container to protect from moisture.
Replace cap securely each time after opening. Do not discard desiccant.
Once opened, use within 3 months.
Discard any unused tablets 3 months after opening the bottle.

Tucatinib Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.